Isolyte S pH 7.4

Generic Name: sodium chloride, sodium gluconate, sodium acetate, potassium chloride, magnesium chloride, sodium phosphate, dibasic and potassium phosphate, monobasic
Dosage Form: injection, solution

Isolyte® S pH 7.4
(Multi-Electrolyte Injection)

Isolyte S pH 7.4 Description

Each 100 mL of Isolyte® S pH 7.4 (Multi-Electrolyte Injection) contains:
Sodium Chloride USP 0.53 g; Sodium Gluconate USP 0.5 g
Sodium Acetate Trihydrate USP 0.37 g; Potassium Chloride USP 0.037 g
Magnesium Chloride Hexahydrate USP 0.03 g
Dibasic Sodium Phosphate Heptahydrate USP 0.012 g
Monobasic Potassium Phosphate NF 0.00082 g; Water for Injection USP qs
pH may be adjusted with Glacial Acetic Acid USP or Sodium Hydroxide NF
pH: 7.4 (7.0–7.8)    Calculated Osmolarity: 295 mOsmol/liter
Concentration of Electrolytes (mEq/liter): Sodium 141; Potassium 5
Magnesium 3; Chloride 98; 1Phosphate (HPO) 1; Acetate (CH3COO) 27 Gluconate (HOCH2(CHOH)4COO) 23

Isolyte® S pH 7.4 is sterile, nonpyrogenic, and contains no bacteriostatic or antimicrobial agents. This product is intended for intravenous administration.

The formulas of the active ingredients are:

Ingredients Molecular
Formula
Molecular
Weight
 Sodium Chloride USP  NaCl    58.44
 Sodium Acetate Trihydrate USP  CH3COONa•3H2O  136.08
 Potassium Chloride USP  KCl    74.55
 Magnesium Chloride Hexahydrate USP  MgCl2•6H2O  203.30
 Dibasic Sodium Phosphate Heptahydrate USP  Na2HPO4•7H2O  268.07
 Monobasic Potassium Phosphate NF  KH2PO4  136.09
 Sodium Gluconate USP  

 218.14

The EXCEL® Container is Latex-free, PVC-free, and DEHP-free.

The plastic container is made from a multilayered film specifically developed for parenteral drugs. It contains no plasticizers and exhibits virtually no leachables. The solution contact layer is a rubberized copolymer of ethylene and propylene. The container is nontoxic and biologically inert. The container-solution unit is a closed system and is not dependent upon entry of external air during administration. The container is overwrapped to provide protection from the physical environment and to provide an additional moisture barrier when necessary.

Addition of medication should be accomplished using complete aseptic technique.

The closure system has two ports; the one for the administration set has a tamper evident plastic protector and the other is a medication addition site. Refer to the Directions for Use of the container.

1
0.5 mmole P/liter

Isolyte S pH 7.4 - Clinical Pharmacology

Isolyte® S pH 7.4 provides electrolytes and is a source of water for hydration. It is capable of inducing diuresis depending on the clinical condition of the patient.

Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid.

Potassium, the principal cation of intracellular fluid, participates in carbohydrate utilization and protein synthesis, and is critical in the regulation of nerve conduction and muscle contraction, particularly in the heart.

Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration.

Phosphate is a major intracellular anion which participates in providing energy for metabolism of substrates and contributes to significant metabolic and enzymatic reactions in almost all organs and tissues. It exerts a modifying influence on calcium levels, a buffering effect on acid-base equilibrium and has a primary role in the renal excretion of hydrogen ions.

Magnesium, a principal cation of soft tissue, is primarily involved in enzyme activity associated with the metabolism of carbohydrates and protein. Magnesium is also involved in neuromuscular irritability.

Gluconate and acetate are organic ions which are hydrogen ion acceptors and contribute bicarbonate during their metabolism to carbon dioxide and water, and serve as alkalinizing agents.

Indications and Usage for Isolyte S pH 7.4

This solution is indicated for use in adults as a source of electrolytes and water for hydration, and as an alkalinizing agent.

Contraindications

Contraindications: None known. Accurate clinical and laboratory estimation of fluid and electrolyte balance in order to access benefit/risk ratio are essential prior to administration of this solution (see WARNINGS and PRECAUTIONS).

Warnings

The administration of intravenous solutions can cause fluid and/or solute overload resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentration. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentration.

Solutions containing sodium ions should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states in which there is sodium retention with edema.

In patients with diminished renal function, administration of solutions containing sodium or potassium ions may result in sodium or potassium retention.

Solutions containing potassium ions should be used with great care, if at all, in patients with hyperkalemia, severe renal failure, and in conditions in which potassium retention is present.

Solutions containing gluconate or acetate should be used with great care in patients with metabolic or respiratory alkalosis and in those conditions in which there is an increased level or an impaired utilization of these ions, such as severe hepatic insufficiency.

Precautions

General

This solution should be used with care in patients with hypervolemia, renal insufficiency, urinary tract obstruction, or impending or frank cardiac decompensation.

Extraordinary electrolyte losses such as may occur during protracted nasogastric suction, vomiting, diarrhea or gastrointestinal fistula drainage may necessitate additional electrolyte supplementation.

Additional essential electrolytes, minerals, and vitamins should be supplied as needed.

Care should be exercised in administering solutions containing sodium or potassium to patients with renal or cardiovascular insufficiency, with or without congestive heart failure, particularly if they are postoperative or elderly.

Potassium therapy should be guided primarily by serial electrocardiograms, especially in patients receiving digitalis. Serum potassium levels are not necessarily indicative of tissue potassium levels.

Solutions containing potassium or magnesium should be used with caution in the presence of cardiac disease, particularly when accompanied by renal disease.

Solutions containing gluconate or acetate should be used with caution. Excess administration may result in metabolic alkalosis.

To minimize the risk of possible incompatibilities arising from mixing this solution with other additives that may be prescribed, the final infusate should be inspected for cloudiness or precipitation immediately after mixing, prior to administration, and periodically during administration.

Do not use plastic container in series connection.

If administration is controlled by a pumping device, care must be taken to discontinue pumping action before the container runs dry or air embolism may result. If administration is not controlled by a pumping device, refrain from applying excessive pressure (>300mmHg) causing distortion to the container such as wringing or twisting. Such handling could result in breakage of the container.

This solution is intended for intravenous administration using sterile equipment. It is recommended that intravenous administration apparatus be replaced at least once every 24 hours.

Use only if solution is clear and container and seals are intact.

Laboratory Tests

Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations, and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation. Significant deviations from normal concentrations may require tailoring of the electrolyte pattern, in this or an alternative solution.

Drug Interactions

Sodium-containing solutions should be administered with caution to patients receiving corticosteroids or corticotropin, or to other salt-retaining patients.

Administration of barbiturates, narcotics, hypnotics or systemic anesthetics should be adjusted with caution in patients also receiving magnesium-containing solutions because of an additive central depressive effect.

Parenteral magnesium should be administered with extreme caution to patients receiving digitalis preparations.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Long term animal studies with Isolyte® S pH 7.4 (Multi-Electrolyte Injection) have not been performed to evaluate the carcinogenic potential, mutagenic potential, or effects on fertility.

Pregnancy

Teratogenic Effects

Pregnancy Category C

Animal reproduction studies have not been conducted with Isolyte® S pH 7.4 (Multi-Electrolyte Injection). It is also not known whether Isolyte® S pH 7.4 can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Isolyte® S pH 7.4 should be given to a pregnant woman only if clearly needed.

Labor and Delivery

As reported in the literature, electrolyte solutions have been administered during labor and delivery. Caution should be exercised, and the fluid balance, glucose and electrolyte concentrations, and acid-base balance, of both mother and fetus should be evaluated periodically or whenever warranted by the condition of the patient or fetus.

Nursing Mothers

Caution should be exercised when Isolyte® S pH 7.4 (Multi-Electrolyte Injection) is administered to a nursing woman.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

Geriatric Use

In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

See WARNINGS.

Adverse Reactions

Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.

Symptoms may result from an excess or deficit of one or more of the ions present in the solution; therefore, frequent monitoring of electrolyte levels is essential.

Hypernatremia may be associated with edema and exacerbation of congestive heart failure due to the retention of water, resulting in an expanded extracellular fluid volume.

Reactions reported with the use of potassium-containing solutions include nausea, vomiting, abdominal pain and diarrhea. The signs and symptoms of potassium intoxication include paresthesias of the extremities, areflexia, muscular or respiratory paralysis, mental confusion, weakness, hypotension, cardiac arrhythmias, heart block, electrocardiographic abnormalities and cardiac arrest. Potassium deficits result in disruption of neuromuscular function, and intestinal ileus and dilatation.

If infused in large amounts, chloride ions may cause a loss of bicarbonate ions, resulting in an acidifying effect.

Phosphorus deficiency may lead to impaired tissue oxygenation and acute hemolytic anemia. Relative to calcium, excessive phosphorus intake can precipitate hypocalcemia with cramps, tetany and muscular hyperexcitability.

Abnormally high plasma levels of magnesium can result in flushing, sweating, hypotension, circulatory collapse, and depression of cardiac and central nervous system function. Respiratory depression is the most immediate threat to life. Magnesium deficits can result in tachycardia, hypertension, hyperirritability and psychotic behavior.

The physician should also be alert to the possibility of adverse reactions to drug additives. Prescribing information for drug additives to be administered in this manner should be consulted.

If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.

Overdosage

In the event of a fluid or solute overload during parenteral therapy, reevaluate the patient's condition, and institute appropriate corrective treatment.

In the event of overdosage with potassium-containing solutions, discontinue the infusion immediately and institute corrective therapy to reduce serum potassium levels.

Treatment of hyperkalemia includes the following:

  1. Dextrose Injection USP, 10% or 25%, containing 10 units of crystalline insulin per 20 grams of dextrose administered intravenously, 300 to 500 mL per hour.
  2. Absorption and exchange of potassium using sodium or ammonium cycle cation exchange resin, orally and as retention enema.
  3. Hemodialysis and peritoneal dialysis. The use of potassium-containing foods or medications must be eliminated. However, in cases of digitalization, too rapid a lowering of plasma potassium concentration can cause digitalis toxicity.

Over-aggressive phosphate replacement may precipitate hypocalcemic tetany. To prevent hypocalcemia, calcium supplementation should always accompany phosphate administration.

Isolyte S pH 7.4 Dosage and Administration

This solution is for intravenous use only.

Dosage is to be directed by a physician and is dependent upon age, weight, clinical condition of the patient and laboratory determinations. Frequent laboratory determinations and clinical evaluation are essential to monitor changes in blood glucose and electrolyte concentrations, and fluid and electrolyte balance during prolonged parenteral therapy.

Fluid administration should be based on calculated maintenance or replacement fluid requirements for each patient.

Isolyte® S pH 7.4 (Multi-Electrolyte Injection) may be admixed with solutions which contain phosphate or which have been supplemented with phosphate.

The presence of magnesium and phosphate ions in this solution should be considered when phosphate is present in the additive solution, in order to avoid precipitation.

Some additives may be incompatible. Consult with pharmacist. When introducing additives, use aseptic techniques. Mix thoroughly. Do not store.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

How is Isolyte S pH 7.4 Supplied

Isolyte® S pH 7.4 (Multi-Electrolyte Injection) is supplied sterile and nonpyrogenic in EXCEL® Containers. The 1000 mL containers are packaged 12 per case and the 500 mL containers are packaged 24 per case.

NDC Cat. No. Size
 Isolyte® S pH 7.4 (Multi-Electrolyte Injection)
 (Canada DIN 01931679)
 0264-7707-00  L7070  1000 mL
 0264-7707-10  L7071  500 mL

Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. Protect from freezing. It is recommended that the product be stored at room temperature (25°C); however, brief exposure up to 40°C does not adversely affect the product.

Rx only

Revised: December 2009

EXCEL and Isolyte are registered trademarks of B. Braun Medical Inc.

Directions for Use of EXCEL® Container

Caution: Do not use plastic container in series connection.

To Open

Tear overwrap down at notch and remove solution container. Check for minute leaks by squeezing solution container firmly. If leaks are found, discard solution as sterility may be impaired. If supplemental medication is desired, follow directions below before preparing for administration.

NOTE: Before use, perform the following checks:

  •  Inspect each container. Read the label. Ensure solution is the one ordered and is within the expiration date.
  •  Invert container and carefully inspect the solution in good light for cloudiness, haze, or particulate matter. Any container which is suspect should not be used.
  •  Use only if solution is clear and container and seals are intact.

Preparation for Administration

  1. Remove plastic protector from sterile set port at bottom of container.
  2. Attach administration set. Refer to complete directions accompanying set.

To Add Medication

Warning: Some additives may be incompatible.

To Add Medication Before Solution Administration

  1. Prepare medication site.
  2. Using syringe with 18–22 gauge needle, puncture medication port and inner diaphragm and inject.
  3. Squeeze and tap ports while ports are upright and mix solution and medication thoroughly.

To Add Medication During Solution Administration

  1. Close clamp on the set.
  2. Prepare medication site.
  3. Using syringe with 18–22 gauge needle of appropriate length (at least 5/8 inch), puncture resealable medication port and inner diaphragm and inject.
  4. Remove container from IV pole and/or turn to an upright position.
  5. Evacuate both ports by tapping and squeezing them while container is in the upright position.
  6. Mix solution and medication thoroughly.
  7. Return container to in use position and continue administration.

B. Braun Medical Inc.
Irvine, CA 92614-5895 USA
Made in USA

In Canada, distributed by:
B. Braun Medical Inc.
Scarborough, Ontario M1H 2W4

Y36-002-722

PRINCIPAL DISPLAY PANEL - 1000 mL Container Label

Isolyte® S pH 7.4
(Multi-Electrolyte Injection)

REF L7070
NDC 0264-7707-00
DIN 01931679
HK 22410

1000 mL
EXCEL® CONTAINER

Electrolytes (mEq/liter):

Na+ 141
K+ 5
Mg++ 3
Cl 98
Acetate 27
Phosphate
(HPO) 1
(0.5 mmole P/L)
Gluconate 23

Each 100 mL contains:
Sodium Chloride USP 0.53 g
Sodium Gluconate USP 0.5 g
Sodium Acetate•3H2O USP 0.37 g
Potassium Chloride USP 0.037 g
Magnesium Chloride•6H2O USP 0.03 g
Dibasic Sodium Phosphate•7H2O USP 0.012 g
Monobasic Potassium Phosphate NF 0.00082 g
Water for Injection USP qs
pH may be adjusted with Glacial Acetic Acid USP
or Sodium Hydroxide NF

pH: 7.4 (7.0-7.8)
Calc. Osmolarity: 295 mOsmol/liter

Sterile, nonpyrogenic. Single dose container.

Do not use in series connection.
For intravenous use only. Use only if solution is clear and
container and seals are intact.

WARNINGS: Some additives may be incompatible. Consult
with pharmacist. When introducing additives, use aseptic
techniques. Mix thoroughly. Do not store.

Recommended Storage:
Room temperature (25°C). Avoid excessive heat. Protect
from freezing. See Package Insert.

Rx only

EXCEL and Isolyte are registered
trademarks of B. Braun Medical Inc.

B. Braun Medical Inc.
Irvine, CA 92614-5895 USA
1-800-227-2862
www.bbraun.com
Made in USA

In Canada, distributed by:
B. Braun Medical Inc.
Scarborough, Ontario M1H 2W4

Y94-003-020
LD-149-2

Do not remove overwrap until ready for use. After removing the
overwrap, check for minute leaks by squeezing container firmly.
If leaks are found, discard solution as sterility may be impaired.

PRINCIPAL DISPLAY PANEL - 500 mL Container Label

Isolyte® S pH 7.4
(Multi-Electrolyte Injection)

REF L7071
NDC 0264-7707-10

DIN 01931679
HK 22410

500 mL
EXCEL® CONTAINER

Electrolytes (mEq/liter):

Na+ 141
K+ 5
Mg++ 3
Cl 98
Acetate 27
Phosphate
(HPO) 1
(0.5 mmole P/L)
Gluconate 23

Each 100 mL contains: Sodium Chloride USP 0.53 g
Sodium Gluconate USP 0.5 g; Sodium Acetate•3H2O USP 0.37 g
Potassium Chloride USP 0.037 g; Magnesium Chloride•6H2O USP 0.03 g
Dibasic Sodium Phosphate•7H2O USP 0.012 g
Monobasic Potassium Phosphate NF 0.00082 g
Water for Injection USP qs
pH may be adjusted with Glacial Acetic Acid USP or Sodium Hydroxide NF

pH: 7.4 (7.0–7.8)
Calc. Osmolarity: 295 mOsmol/liter

Sterile, nonpyrogenic. Single dose container.

Do not use in series connection. For intravenous use only.
Use only if solution is clear and container and seals are intact.

WARNINGS: Some additives may be incompatible. Consult with pharmacist.
When introducing additives, use aseptic techniques. Mix thoroughly. Do not store.

Recommended Storage: Room temperature (25°C).
Avoid excessive heat. Protect from freezing. See Package Insert.

Rx only

EXCEL and Isolyte are registered trademarks of B. Braun Medical Inc.

B. Braun Medical Inc.
Irvine, CA 92614-5895 USA
Made in USA

In Canada, distributed by:
B. Braun Medical Inc.
Scarborough, Ontario M1H 2W4

Y94-003-021
LD-148-2

Do not remove overwrap until ready for use. After removing the overwrap,
check for minute leaks by squeezing container firmly. If leaks are found,
discard solution as sterility may be impaired.

Isolyte S pH 7.4 
sodium chloride, sodium gluconate, sodium acetate, potassium chloride, magnesium chloride, sodium phosphate, dibasic, and potassium phosphate injection, solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0264-7707
Route of Administration INTRAVENOUS DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
SODIUM CHLORIDE (SODIUM CATION and CHLORIDE ION) SODIUM CHLORIDE 0.53 g  in 100 mL
SODIUM GLUCONATE (SODIUM CATION and GLUCONIC ACID) SODIUM GLUCONATE 0.5 g  in 100 mL
SODIUM ACETATE (SODIUM CATION and ACETATE ION) SODIUM ACETATE 0.37 g  in 100 mL
POTASSIUM CHLORIDE (POTASSIUM CATION and CHLORIDE ION) POTASSIUM CHLORIDE 0.037 g  in 100 mL
MAGNESIUM CHLORIDE (MAGNESIUM CATION and CHLORIDE ION) MAGNESIUM CHLORIDE 0.03 g  in 100 mL
SODIUM PHOSPHATE, DIBASIC (SODIUM CATION and PHOSPHATE ION) SODIUM PHOSPHATE, DIBASIC 0.012 g  in 100 mL
POTASSIUM PHOSPHATE, MONOBASIC (PHOSPHATE ION and POTASSIUM CATION) POTASSIUM PHOSPHATE, MONOBASIC 0.00082 g  in 100 mL
Inactive Ingredients
Ingredient Name Strength
WATER  
Packaging
# Item Code Package Description
1 NDC:0264-7707-00 12 CONTAINER (12 CONTAINER) in 1 CASE
1 1000 mL in 1 CONTAINER
2 NDC:0264-7707-10 24 CONTAINER (24 CONTAINER) in 1 CASE
2 500 mL in 1 CONTAINER
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA019696 09/29/1989
Labeler - B. Braun Medical Inc. (002397347)
Revised: 03/2014
 
B. Braun Medical Inc.
Hide
(web3)